Efficacy News and Research

RSS

New approach for cervical cancer vaccines based on microsphere-encapsulated peptides

Infection with HPV16, a high-risk human papillomavirus (HPV), can cause cervical cancer in humans. These infections carry a high risk of morbidity and mortality globally in females.

29 Oct 2024

Boosting Treg cells shows promise in preventing recurrent pregnancy loss

Recurrent pregnancy loss can be devastating and exert a major impact on women, their partners, and society more broadly, but currently there are few options for effective therapies.

29 Oct 2024

Research uncovers intrinsic factors influencing CAR-T cell success

Researchers from the Josep Carreras Leukaemia Research Institute have found that the efficacy of varni-cel, a CAR-T infusion product for B-ALL patients, is highly dependent on intrinsic features of the CAR-T cells themselves and their progression within the patient.

29 Oct 2024

Scientists discover novel compound to combat age-related blindness

Rensselaer Polytechnic Institute's Christopher Cioffi, Ph.D., Thomas and Constance D'Ambra Professor in Organic Chemistry, has been collaborating with Konstantin Petrukhin, Ph.D., Professor of Ophthalmic Science at Colombia University, to develop compounds to treat dry age-related macular degeneration (AMD) and Stargardt disease - both blindness-causing diseases.

28 Oct 2024

Study highlights importance of RSV vaccination for high-risk populations

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines.

28 Oct 2024

Novel class of encrypted peptides offers hope against drug-resistant bacteria

In a significant advance against the growing threat of antibiotic-resistant bacteria, researchers have identified a novel class of antimicrobial agents known as encrypted peptides, which may expand the immune system's arsenal of tools to fight infection.

28 Oct 2024

Study finds pistachios might help guard against vision loss

A study finds that pistachio consumption significantly increases macular pigment optical density, potentially protecting against vision loss in healthy adults.

28 Oct 2024

Ozempic effective for patients with chronic kidney damage

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic kidney disease and obesity.

28 Oct 2024

Expanded access to weight-loss drugs could save thousands of lives

Researchers explore the potential benefits of expanding access to novel weight loss drugs to enhance survival rates in overweight and obese individuals.

28 Oct 2024

Clinical trial highlights efficacy of imlifidase for kidney transplant recipients

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX) - a procedure that removes antibodies from the plasma portion of the blood.

27 Oct 2024

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial.

27 Oct 2024

Bioactive peptides from Chlorella vulgaris for therapeutic applications

Chlorella vulgaris is a green, photosynthetic microalga in the phylum Chlorophyta. The goal of our study was to perform a bioinformatics analysis of Photosystem I P700 chlorophyll a apoprotein A2, one of its photosynthesis-related proteins, and to hunt for potent bioactive peptides.

27 Oct 2024

New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface.

26 Oct 2024

New analysis confirms canagliflozin's cardiovascular and kidney benefits in older adults

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age.

26 Oct 2024

MHRA greenlights donanemab for early stage Alzheimer’s disease

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the medicine donanemab (Kisunla) for use in the early stages of Alzheimer’s disease, following a thorough review of the benefits and risks.

26 Oct 2024

New research trial aims to address a disabling post-stroke condition

A major new research trial led by academics at the University of East Anglia (UEA) and taking place at eight major stroke centres across England, will test the efficacy of a new therapy for a disabling post-stroke condition that affects around one in three survivors, thanks to a £1.26m grant from the Efficacy and Mechanism Evaluation (EME) Programme - a partnership between the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC).

26 Oct 2024

Extracellular vesicles play key role in cancer drug resistance

Despite significant advancements in cancer treatment, drug resistance remains a persistent challenge. Cancer cells can often develop resistance to treatments such as chemotherapy, radiotherapy, and immunotherapy, leading to reduced treatment efficacy.

25 Oct 2024

UCLA researchers identify key protein in heart healing after attack

UCLA scientists have identified the protein GPNMB as a critical regulator in the heart's healing process after a heart attack.

25 Oct 2024

Key mutations discovered in cancer cells linked to WRN inhibitor resistance

Researchers have discovered key mutations in certain cancer cells that make them resistant to WRN inhibitors, a new class of anti-cancer drugs.

24 Oct 2024

Antibiotic for liver disease linked to emergence of antimicrobial resistant superbug

An international team of researchers has found that an antibiotic commonly prescribed for patients with liver disease, called rifaximin, has led to the global emergence of an almost untreatable form of the antimicrobial resistant superbug vancomycin-resistant enterococcus faecium (VRE), which frequently causes serious infections in hospitalized patients.

24 Oct 2024